Financhill
Sell
40

DHR Quote, Financials, Valuation and Earnings

Last price:
$231.09
Seasonality move :
10.08%
Day range:
$229.17 - $231.49
52-week range:
$222.53 - $281.70
Dividend yield:
0.45%
P/E ratio:
44.14x
P/S ratio:
7.22x
P/B ratio:
3.26x
Volume:
1.5M
Avg. volume:
3.3M
1-year change:
-0.05%
Market cap:
$167B
Revenue:
$23.9B
EPS (TTM):
$5.24

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
DHR
Danaher
$5.6B $1.57 -0.26% 48.15% $287.70
CTSO
CytoSorbents
$10.2M -$0.06 28.63% -41.38% --
DCTH
Delcath Systems
$10.5M -$0.19 2204.21% -93.94% --
DGX
Quest Diagnostics
$2.4B $2.26 12.75% 28.89% $169.96
PGNY
Progyny
$297.4M $0.37 2.66% 183.52% $30.22
STRR
Star Equity Holdings
$13.2M -$0.32 21.89% -605.27% --
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
DHR
Danaher
$231.28 $287.70 $167B 44.14x $0.27 0.45% 7.22x
CTSO
CytoSorbents
$0.90 -- $49.5M -- $0.00 0% 1.40x
DCTH
Delcath Systems
$11.97 -- $382.7M -- $0.00 0% 14.35x
DGX
Quest Diagnostics
$153.02 $169.96 $17.1B 20.57x $0.75 1.93% 1.80x
PGNY
Progyny
$14.71 $30.22 $1.3B 25.36x $0.00 0% 1.27x
STRR
Star Equity Holdings
$2.18 -- $7M 0.70x $0.00 0% 0.14x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
DHR
Danaher
25.46% 0.578 8.73% 0.84x
CTSO
CytoSorbents
51.51% 0.791 16.8% 1.46x
DCTH
Delcath Systems
18.92% 0.853 0.79% 0.97x
DGX
Quest Diagnostics
47.86% -0.146 35.62% 1.02x
PGNY
Progyny
-- 1.563 -- 2.48x
STRR
Star Equity Holdings
15.99% -0.852 31.89% 1.35x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
DHR
Danaher
$3.4B $958M 5.5% 7.47% 18.35% $1.2B
CTSO
CytoSorbents
$4.5M -$4.4M -70.49% -103.21% -20.27% -$2.8M
DCTH
Delcath Systems
$9.6M -$1.3M -167.55% -251.36% -11.24% -$3.9M
DGX
Quest Diagnostics
$811M $330M 7.3% 12.68% 14.23% $250M
PGNY
Progyny
$59.2M $12.5M 11.31% 11.31% 4.35% $42.7M
STRR
Star Equity Holdings
$2.8M -$5.3M -9.23% -10.13% -38.95% $420K

Danaher vs. Competitors

  • Which has Higher Returns DHR or CTSO?

    CytoSorbents has a net margin of 14.11% compared to Danaher's net margin of -27.1%. Danaher's return on equity of 7.47% beat CytoSorbents's return on equity of -103.21%.

    Company Gross Margin Earnings Per Share Invested Capital
    DHR
    Danaher
    58.66% $1.12 $68.8B
    CTSO
    CytoSorbents
    52.3% -$0.04 $26.8M
  • What do Analysts Say About DHR or CTSO?

    Danaher has a consensus price target of $287.70, signalling upside risk potential of 24.39%. On the other hand CytoSorbents has an analysts' consensus of -- which suggests that it could grow by 455.56%. Given that CytoSorbents has higher upside potential than Danaher, analysts believe CytoSorbents is more attractive than Danaher.

    Company Buy Ratings Hold Ratings Sell Ratings
    DHR
    Danaher
    18 5 0
    CTSO
    CytoSorbents
    0 0 0
  • Is DHR or CTSO More Risky?

    Danaher has a beta of 0.832, which suggesting that the stock is 16.801% less volatile than S&P 500. In comparison CytoSorbents has a beta of 0.568, suggesting its less volatile than the S&P 500 by 43.192%.

  • Which is a Better Dividend Stock DHR or CTSO?

    Danaher has a quarterly dividend of $0.27 per share corresponding to a yield of 0.45%. CytoSorbents offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Danaher pays 26.2% of its earnings as a dividend. CytoSorbents pays out -- of its earnings as a dividend. Danaher's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios DHR or CTSO?

    Danaher quarterly revenues are $5.8B, which are larger than CytoSorbents quarterly revenues of $8.6M. Danaher's net income of $818M is higher than CytoSorbents's net income of -$2.3M. Notably, Danaher's price-to-earnings ratio is 44.14x while CytoSorbents's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Danaher is 7.22x versus 1.40x for CytoSorbents. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    DHR
    Danaher
    7.22x 44.14x $5.8B $818M
    CTSO
    CytoSorbents
    1.40x -- $8.6M -$2.3M
  • Which has Higher Returns DHR or DCTH?

    Delcath Systems has a net margin of 14.11% compared to Danaher's net margin of 16.64%. Danaher's return on equity of 7.47% beat Delcath Systems's return on equity of -251.36%.

    Company Gross Margin Earnings Per Share Invested Capital
    DHR
    Danaher
    58.66% $1.12 $68.8B
    DCTH
    Delcath Systems
    85.36% $0.06 $10.6M
  • What do Analysts Say About DHR or DCTH?

    Danaher has a consensus price target of $287.70, signalling upside risk potential of 24.39%. On the other hand Delcath Systems has an analysts' consensus of -- which suggests that it could grow by 78.22%. Given that Delcath Systems has higher upside potential than Danaher, analysts believe Delcath Systems is more attractive than Danaher.

    Company Buy Ratings Hold Ratings Sell Ratings
    DHR
    Danaher
    18 5 0
    DCTH
    Delcath Systems
    0 0 0
  • Is DHR or DCTH More Risky?

    Danaher has a beta of 0.832, which suggesting that the stock is 16.801% less volatile than S&P 500. In comparison Delcath Systems has a beta of 0.851, suggesting its less volatile than the S&P 500 by 14.882%.

  • Which is a Better Dividend Stock DHR or DCTH?

    Danaher has a quarterly dividend of $0.27 per share corresponding to a yield of 0.45%. Delcath Systems offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Danaher pays 26.2% of its earnings as a dividend. Delcath Systems pays out -- of its earnings as a dividend. Danaher's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios DHR or DCTH?

    Danaher quarterly revenues are $5.8B, which are larger than Delcath Systems quarterly revenues of $11.2M. Danaher's net income of $818M is higher than Delcath Systems's net income of $1.9M. Notably, Danaher's price-to-earnings ratio is 44.14x while Delcath Systems's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Danaher is 7.22x versus 14.35x for Delcath Systems. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    DHR
    Danaher
    7.22x 44.14x $5.8B $818M
    DCTH
    Delcath Systems
    14.35x -- $11.2M $1.9M
  • Which has Higher Returns DHR or DGX?

    Quest Diagnostics has a net margin of 14.11% compared to Danaher's net margin of 9.08%. Danaher's return on equity of 7.47% beat Quest Diagnostics's return on equity of 12.68%.

    Company Gross Margin Earnings Per Share Invested Capital
    DHR
    Danaher
    58.66% $1.12 $68.8B
    DGX
    Quest Diagnostics
    32.6% $1.99 $13.2B
  • What do Analysts Say About DHR or DGX?

    Danaher has a consensus price target of $287.70, signalling upside risk potential of 24.39%. On the other hand Quest Diagnostics has an analysts' consensus of $169.96 which suggests that it could grow by 11.07%. Given that Danaher has higher upside potential than Quest Diagnostics, analysts believe Danaher is more attractive than Quest Diagnostics.

    Company Buy Ratings Hold Ratings Sell Ratings
    DHR
    Danaher
    18 5 0
    DGX
    Quest Diagnostics
    8 9 0
  • Is DHR or DGX More Risky?

    Danaher has a beta of 0.832, which suggesting that the stock is 16.801% less volatile than S&P 500. In comparison Quest Diagnostics has a beta of 0.893, suggesting its less volatile than the S&P 500 by 10.74%.

  • Which is a Better Dividend Stock DHR or DGX?

    Danaher has a quarterly dividend of $0.27 per share corresponding to a yield of 0.45%. Quest Diagnostics offers a yield of 1.93% to investors and pays a quarterly dividend of $0.75 per share. Danaher pays 26.2% of its earnings as a dividend. Quest Diagnostics pays out 36.77% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios DHR or DGX?

    Danaher quarterly revenues are $5.8B, which are larger than Quest Diagnostics quarterly revenues of $2.5B. Danaher's net income of $818M is higher than Quest Diagnostics's net income of $226M. Notably, Danaher's price-to-earnings ratio is 44.14x while Quest Diagnostics's PE ratio is 20.57x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Danaher is 7.22x versus 1.80x for Quest Diagnostics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    DHR
    Danaher
    7.22x 44.14x $5.8B $818M
    DGX
    Quest Diagnostics
    1.80x 20.57x $2.5B $226M
  • Which has Higher Returns DHR or PGNY?

    Progyny has a net margin of 14.11% compared to Danaher's net margin of 3.64%. Danaher's return on equity of 7.47% beat Progyny's return on equity of 11.31%.

    Company Gross Margin Earnings Per Share Invested Capital
    DHR
    Danaher
    58.66% $1.12 $68.8B
    PGNY
    Progyny
    20.67% $0.11 $434.9M
  • What do Analysts Say About DHR or PGNY?

    Danaher has a consensus price target of $287.70, signalling upside risk potential of 24.39%. On the other hand Progyny has an analysts' consensus of $30.22 which suggests that it could grow by 28.19%. Given that Progyny has higher upside potential than Danaher, analysts believe Progyny is more attractive than Danaher.

    Company Buy Ratings Hold Ratings Sell Ratings
    DHR
    Danaher
    18 5 0
    PGNY
    Progyny
    4 4 0
  • Is DHR or PGNY More Risky?

    Danaher has a beta of 0.832, which suggesting that the stock is 16.801% less volatile than S&P 500. In comparison Progyny has a beta of 1.350, suggesting its more volatile than the S&P 500 by 34.952%.

  • Which is a Better Dividend Stock DHR or PGNY?

    Danaher has a quarterly dividend of $0.27 per share corresponding to a yield of 0.45%. Progyny offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Danaher pays 26.2% of its earnings as a dividend. Progyny pays out -- of its earnings as a dividend. Danaher's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios DHR or PGNY?

    Danaher quarterly revenues are $5.8B, which are larger than Progyny quarterly revenues of $286.6M. Danaher's net income of $818M is higher than Progyny's net income of $10.4M. Notably, Danaher's price-to-earnings ratio is 44.14x while Progyny's PE ratio is 25.36x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Danaher is 7.22x versus 1.27x for Progyny. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    DHR
    Danaher
    7.22x 44.14x $5.8B $818M
    PGNY
    Progyny
    1.27x 25.36x $286.6M $10.4M
  • Which has Higher Returns DHR or STRR?

    Star Equity Holdings has a net margin of 14.11% compared to Danaher's net margin of -14.42%. Danaher's return on equity of 7.47% beat Star Equity Holdings's return on equity of -10.13%.

    Company Gross Margin Earnings Per Share Invested Capital
    DHR
    Danaher
    58.66% $1.12 $68.8B
    STRR
    Star Equity Holdings
    20.62% -$0.78 $69.5M
  • What do Analysts Say About DHR or STRR?

    Danaher has a consensus price target of $287.70, signalling upside risk potential of 24.39%. On the other hand Star Equity Holdings has an analysts' consensus of -- which suggests that it could grow by 358.72%. Given that Star Equity Holdings has higher upside potential than Danaher, analysts believe Star Equity Holdings is more attractive than Danaher.

    Company Buy Ratings Hold Ratings Sell Ratings
    DHR
    Danaher
    18 5 0
    STRR
    Star Equity Holdings
    0 0 0
  • Is DHR or STRR More Risky?

    Danaher has a beta of 0.832, which suggesting that the stock is 16.801% less volatile than S&P 500. In comparison Star Equity Holdings has a beta of 0.080, suggesting its less volatile than the S&P 500 by 91.951%.

  • Which is a Better Dividend Stock DHR or STRR?

    Danaher has a quarterly dividend of $0.27 per share corresponding to a yield of 0.45%. Star Equity Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Danaher pays 26.2% of its earnings as a dividend. Star Equity Holdings pays out 7.62% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios DHR or STRR?

    Danaher quarterly revenues are $5.8B, which are larger than Star Equity Holdings quarterly revenues of $13.7M. Danaher's net income of $818M is higher than Star Equity Holdings's net income of -$2M. Notably, Danaher's price-to-earnings ratio is 44.14x while Star Equity Holdings's PE ratio is 0.70x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Danaher is 7.22x versus 0.14x for Star Equity Holdings. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    DHR
    Danaher
    7.22x 44.14x $5.8B $818M
    STRR
    Star Equity Holdings
    0.14x 0.70x $13.7M -$2M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Uber Stock a Buy on the Dip?
Is Uber Stock a Buy on the Dip?

Shares of Uber Technologies (NYSE:UBER) have been fading fast in…

Is AMD Stock an All-Time Buy?
Is AMD Stock an All-Time Buy?

Advanced Micro Devices (NASDAQ:AMD) is a high-growth AI stock that…

How High Will Airbnb Stock Go?
How High Will Airbnb Stock Go?

Airbnb, Inc. (NASDAQ:ABNB) share price has seen substantial turbulence over…

Stock Ideas

Buy
65
Is AAPL Stock a Buy?

Market Cap: $3.9T
P/E Ratio: 43x

Buy
56
Is NVDA Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 117x

Buy
57
Is MSFT Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 37x

Alerts

Buy
64
ARQQ alert for Dec 27

Arqit Quantum [ARQQ] is down 3.22% over the past day.

Buy
64
QMCO alert for Dec 27

Quantum [QMCO] is up 4.72% over the past day.

Buy
65
ALGS alert for Dec 27

Aligos Therapeutics [ALGS] is down 4.82% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock